Industry experts discussed how recessive dystrophic epidermolysis bullosa can serve as a model for cell and gene therapy during an episode of Denatured, according to a Jun. 18 episode. The conversation featured Mark Lowdell, chief scientific officer and co-founder at INmuneBio Inc., and Vishwas Seshadri, chief executive officer and director at Abeona Therapeutics.
The discussion explored what this ultra-rare disease reveals about scaling advanced treatments in the future. Host Jennifer C. Smith-Parker, director of insights at BioSpace, led the conversation with Lowdell and Seshadri as guests.
Listeners were invited to tune in on multiple platforms including Spotify, Apple Podcasts, Amazon Music, and iHeart. The program examined the implications of treating fragile skin conditions like RDEB with emerging living medicines.
A disclaimer stated that "the views expressed in this discussion by guests are their own and do not represent those of their organizations."
